Market Overview:
The global endometriosis therapies market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of endometriosis, rising awareness about available treatments, and technological advancements in the field of endometriosis therapies. Based on type, the hormonal contraceptives segment is expected to account for the largest share of the global endometriosis therapies market in 2018. This segment is projected to grow at a CAGR of 5.9% from 2018 to 2030 due to its high adoption rate among women with endometriosis and growing awareness about its benefits. Based on application, hospitals are expected to account for the largest share of the globalendome triosismarketin2018.
Product Definition:
Endometriosis therapies are treatments used to manage endometriosis. There are a number of different therapies that can be used, including medications, surgery, and other treatments. The type of therapy used will depend on the severity of the endometriosis and the woman's symptoms. Endometriosis therapies can help reduce pain and inflammation, as well as improve fertility in women who desire to become pregnant.
Hormonal Contraceptives:
Hormonal contraceptives are drugs that act as a barrier between the sperm and ovum. The most commonly used hormonal contraceptive drug is oral contraception, which includes pills, implants, and intra-uterine devices (IUD).
Gonadotropin-releasingHormone(Gn-RH)Agonists:
Gonadotropin-releasing hormone (Gn-RH) agonists are a group of drugs that act on the pituitary gland to release luteinizing hormone (LH). It is used as an anti-endometrial agent in the treatment of severe menstrual pain.
Application Insights:
Based on application, the global endometriosis therapies market is segmented into hospital, clinic and others. The other applications include online therapy and self-referral clinics. Hospital dominated the overall application segment with a revenue share of over 60% in 2017 owing to its ability to offer advanced treatment for women suffering from chronic pelvic pain & infertility due to endometriosis. Moreover, it offers minimally invasive surgeries that enable easier recovery time as compared to other outpatient procedures.
The growth of this segment can be attributed to factors such as increasing awareness about available treatments coupled with rising adoption of these therapies among healthcare professionals across the globe.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing prevalence of endometriosis, rising awareness about treatment options, availability of effective therapies and presence of well-established healthcare facilities. Moreover, high adoption rate for technologically advanced medical products is also propelling growth in this region.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to improving healthcare infrastructure and growing target population base in emerging countries such as China and India. In addition, increasing government initiatives for spreading awareness about endometriosis treatments are expected to drive regional market during the forecast period. For instance; in 2015 Ministry Of Health & Family Welfare (MoHFW) Government Of India launched a national program called—Endometriosis Awareness Programmes (EPAP).
Growth Factors:
- Increasing incidence of endometriosis
- Growing awareness about endometriosis and its treatment options
- Rising demand for minimally invasive therapies for endometriosis
- Technological advancements in the field of endometriosis therapies
- Growing number of clinical studies on new treatments for endometriosis
Scope Of The Report
Report Attributes
Report Details
Report Title
Endometriosis Therapies Market Research Report
By Type
Hormonal Contraceptives, Gonadotropin-releasingHormone(Gn-RH)Agonists, Progestin Therapy, Aromatase Inhibitors
By Application
Hospital, Clinic, Other
By Companies
AbbVie, Eli Lilly, AstraZeneca, Bayer, Astellas Pharma, Meditrina Pharmaceuticals, Pfizer, Neurocrine Biosciences, Takeda Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
138
Number of Tables & Figures
97
Customization Available
Yes, the report can be customized as per your need.
Global Endometriosis Therapies Market Report Segments:
The global Endometriosis Therapies market is segmented on the basis of:
Types
Hormonal Contraceptives, Gonadotropin-releasingHormone(Gn-RH)Agonists, Progestin Therapy, Aromatase Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Eli Lilly
- AstraZeneca
- Bayer
- Astellas Pharma
- Meditrina Pharmaceuticals
- Pfizer
- Neurocrine Biosciences
- Takeda Pharmaceutical
Highlights of The Endometriosis Therapies Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hormonal Contraceptives
- Gonadotropin-releasingHormone(Gn-RH)Agonists
- Progestin Therapy
- Aromatase Inhibitors
- By Application:
- Hospital
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Endometriosis Therapies Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Endometriosis therapies are treatments that aim to improve the symptoms of endometriosis. These may include surgery, medication, and/or therapy.
Some of the major companies in the endometriosis therapies market are AbbVie, Eli Lilly, AstraZeneca, Bayer, Astellas Pharma, Meditrina Pharmaceuticals, Pfizer, Neurocrine Biosciences, Takeda Pharmaceutical.
The endometriosis therapies market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Endometriosis Therapies Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Endometriosis Therapies Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Endometriosis Therapies Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Endometriosis Therapies Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Endometriosis Therapies Market Size & Forecast, 2020-2028
4.5.1 Endometriosis Therapies Market Size and Y-o-Y Growth
4.5.2 Endometriosis Therapies Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Hormonal Contraceptives
5.2.2 Gonadotropin-releasingHormone(Gn-RH)Agonists
5.2.3 Progestin Therapy
5.2.4 Aromatase Inhibitors
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Endometriosis Therapies Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Endometriosis Therapies Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Hormonal Contraceptives
9.6.2 Gonadotropin-releasingHormone(Gn-RH)Agonists
9.6.3 Progestin Therapy
9.6.4 Aromatase Inhibitors
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Hormonal Contraceptives
10.6.2 Gonadotropin-releasingHormone(Gn-RH)Agonists
10.6.3 Progestin Therapy
10.6.4 Aromatase Inhibitors
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Hormonal Contraceptives
11.6.2 Gonadotropin-releasingHormone(Gn-RH)Agonists
11.6.3 Progestin Therapy
11.6.4 Aromatase Inhibitors
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Hormonal Contraceptives
12.6.2 Gonadotropin-releasingHormone(Gn-RH)Agonists
12.6.3 Progestin Therapy
12.6.4 Aromatase Inhibitors
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Hormonal Contraceptives
13.6.2 Gonadotropin-releasingHormone(Gn-RH)Agonists
13.6.3 Progestin Therapy
13.6.4 Aromatase Inhibitors
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Endometriosis Therapies Market: Competitive Dashboard
14.2 Global Endometriosis Therapies Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie
14.3.2 Eli Lilly
14.3.3 AstraZeneca
14.3.4 Bayer
14.3.5 Astellas Pharma
14.3.6 Meditrina Pharmaceuticals
14.3.7 Pfizer
14.3.8 Neurocrine Biosciences
14.3.9 Takeda Pharmaceutical
